- Current report filing (8-K)
April 01 2010 - 3:36PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities and Exchange Act of 1934
Date of Report (Date of earliest reported event): March 30, 2010
GEOPHARMA, INC.
(Exact name of registrant as specified in charter)
|
|
|
|
|
|
|
Florida
|
|
001-16185
|
|
59-2600232
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
6950 Bryan Dairy Road, Largo, Florida
|
|
33777
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant's telephone number, including area code: (727) 544-8866
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item
5.07 Submission of Matters to a Vote of Security Holders.
At the 2009 Annual Meeting of Shareholders of GeoPharma, Inc. (the "Company") held on March 30, 2010, the shareholders elected each of the Company's nominees for director to serve until their respective class is renominated and until their successors are elected and qualified; shareholders approved to amend the Company's articles of incorporation to increase the authorized common stock to 100 million; shareholders approved the Company's 2009 Incentive Stock Plan; shareholders approved the Second Amended and Restated Purchase Agreement with Whitebox and thereby approved the possible issuance of more than 20% of the Company's issued common stock outstanding and shareholders also ratified the Audit Committee's selection of Brimmer, Burek & Keelan LLP to serve as the Company's independent registered public accounting firm for fiscal 2009.
The table below shows the voting results:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For
|
|
Withheld
|
|
|
|
|
|
EElection of Directors
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
H Jugal K. Taneja
|
|
|
9,704,710
|
|
|
|
593,564
|
|
|
|
|
|
|
|
|
|
|
B Carol Dore-Falcone
|
|
|
10,204,463
|
|
|
|
93,811
|
|
|
|
|
|
|
|
|
|
|
William L. LaGamba
|
|
|
10,214,198
|
|
|
|
84,076
|
|
|
|
|
|
|
|
|
|
|
Dr. Barry H. Dash
|
|
|
10,206,419
|
|
|
|
91,855
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For
|
|
|
|
Against
|
|
|
|
Abstain
|
|
|
|
|
|
|
Approval to amend the articles of incorporation to increase
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
the authorized common stock outstanding to 100 million
|
|
|
9,740,668
|
|
|
|
320,275
|
|
|
|
37,331
|
|
|
|
|
|
|
Approval of the 2009 Incentive Stock Plan
|
|
|
9,346,910
|
|
|
|
436,674
|
|
|
|
514,690
|
|
|
|
|
|
|
AApproval of the Second Amended and Restated Purchase
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
A Agreement with Whitebox and thereby approved the
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
P possible issuance of more than 20% of the Company's
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
I issued common stock outstanding
|
|
|
10,067,930
|
|
|
|
188,866
|
|
|
|
41,476
|
|
|
|
|
|
|
Ratify Brimmer, Burek & Keelan LLP as the Company's
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
S fiscal 2009 independent registered public accounting firm
|
|
|
10,245,058
|
|
|
|
22,049
|
|
|
|
31,167
|
|
|
|
|
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorize
|
|
|
|
|
|
|
GEOPHARMA, INC.
|
|
|
|
|
Date: April 01, 2010
|
|
/s/ Mihir K. Taneja
|
|
|
|
Mihir K. Taneja,
|
|
|
|
Chief Executive Officer
|
|
|
|
|
|
|
/s/ Carol Dore-Falcone
|
|
|
|
Carol Dore-Falcone,
|
|
|
|
Senior Vice President and Chief Financial Officer
|
Geopharma (NASDAQ:GORX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Geopharma (NASDAQ:GORX)
Historical Stock Chart
From Apr 2023 to Apr 2024
